Market Overview

Enrollment Completed in Flex Pharma's Phase 2 Exploratory Spasticity Study in MS

Share:

-- Company to Report Results Late Q1 2018 --

Click
to Tweet this News

Flex
Pharma, Inc.
(NASDAQ:FLKS), a clinical-stage biotechnology company
that is developing innovative and proprietary treatments in Phase 2
randomized, controlled trials for cramps and spasticity associated with
severe neurological diseases such as multiple sclerosis (MS),
Charcot-Marie-Tooth (CMT) and amyotrophic lateral sclerosis (ALS) under
FDA Fast Track designation, today announced that it has completed
enrollment in its Phase 2 exploratory spasticity study in multiple
sclerosis (MS) with approximately 50 patients in Australia. The
randomized, placebo-controlled, blinded, cross-over study is designed to
evaluate the safety and efficacy of FLX-787, the Company's single
molecule, chemically synthesized, dual A1/V1 transient receptor
potential (TRPA1/V1) ion channel activator, in patients who suffer from
spasticity, cramps and spasms as a consequence of MS.

MS is an autoimmune disease in which inflammatory lesions cause
demyelination, and eventually degeneration, of nerve cells over years.
This loss of nerve function can result in a variety of neurological
deficits such as loss of sensation, vision, and muscle control and
coordination, including spasticity. Spasticity is caused by damage to
motor neurons in the brain and spinal cord. These lesions unmask
hyperactive muscle stretch reflexes that result in persistent electrical
activity in the muscle. This aberrant electrical activity – like that
seen in muscle cramping – can be measured by electromyography (EMG).
This stretch-triggered electrical activity in the muscle produces muscle
stiffness during motion, or spasticity. We believe that this reflex
hyperexcitability, like the alpha motor neuron hyperexcitability that
produces cramping, can benefit from greater inhibition in the spinal
circuitry generated by chemical neurostimulation with TRP activators
like FLX-787. According to the National Institute of Neurological
Disorders and Stroke, between 250,000 and 350,000 people in the United
States suffer from MS and approximately 84% of patients with MS
experience spasticity. This spasticity can be moderate to severe in
almost half of the population, and the need for treatment to alleviate
it increases as the disease progresses.

"Neurologists have very limited therapeutic options for patients
suffering from MS spasticity and the current options are often
suboptimal due to their associated side effects," stated Flex Pharma
Chief Medical Officer Thomas Wessel, M.D., Ph.D. "Our approach offers a
potential important advantage as the drug candidate may reduce cramps or
spasticity without the sedating side effects of many current therapies."

"Given the recent ALS data supporting the efficacy signal of FLX-787
across multiple endpoints related to cramping and the associated pain,
we are more encouraged that FLX-787 may demonstrate a similar effect in
this larger exploratory MS study when we have the results at the end of
the first quarter of next year," said Dr. William McVicar, Flex Pharma
President and CEO. "With data readouts in MS, ALS, and CMT expected over
the next year, we are excited to advance the development of FLX-787 in
multiple neurological settings to help these patients who have very
limited treatment options to address their chronic cramping and
spasticity."

About Flex Pharma

Flex Pharma, Inc. is a clinical-stage biotechnology company that is
developing innovative and proprietary treatments in Phase 2 randomized,
controlled trials for cramps and spasticity associated with the severe
neurological diseases of ALS, MS and peripheral neuropathies such as
Charcot-Marie-Tooth (CMT). The Company's lead candidate, FLX-787, is
being developed under Fast Track designation for the treatment of severe
muscle cramps associated with ALS. Flex Pharma was founded by National
Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate),
and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels
and neurobiology, along with Christoph Westphal, M.D., Ph.D.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things, the design and timing of
ongoing and anticipated clinical trials, including the timing for
results of our clinical trials. These forward-looking statements are
based on management's expectations and assumptions as of the date of
this press release and are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those
expressed or implied by such statements. These risks and uncertainties
include, without limitation: the status, timing, costs, results and
interpretation of our clinical studies; the uncertainties inherent in
conducting clinical studies; our ability to enroll patients in each of
clinical studies on a timely basis; expectations of our ability to make
regulatory filings and obtain and maintain regulatory approvals;
availability of funding sufficient for our foreseeable and unforeseeable
operating expenses and capital expenditure requirements; the inherent
uncertainties associated with intellectual property; and other factors
discussed in greater detail under the heading "Risk Factors" in our
Annual Report on Form 10-K for the year ended December 31, 2016 and
subsequent filings with the Securities and Exchange Commission (SEC).
You are encouraged to read our filings with the SEC, available at www.sec.gov,
for a discussion of these and other risks and uncertainties. Any
forward-looking statements that we make in this press release speak only
as of the date of this press release. We assume no obligation to update
our forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press release.

View Comments and Join the Discussion!
 

Partner Center